Regeneron Pharmaceuticals has reportedly made a series of impactful moves, all of which could significantly affect its valuation. The company has exceeded Q4 earnings expectations with an EPS that shines. TD Cowen has increased Regeneron's price target while shares have also been purchased by TD Waterhouse Canada. Notably, this pharmaceutical giant is expected to show robust growth by 2026. However, its margin slippage could potentially challenge the bullish earnings growth narrative. Other significant highlights include the acquisition of new shares in Regeneron by Summit Global Investments, its exceeding of expectations in quarterly earnings results by $0.96 EPS, and the purchase of 15,006 shares by the Bank of New York Mellon Corp.
Evercore ISI underscores Dupixent and Eylea HD as key growth drivers for Regeneron, potentially pushing the company's dividend to $0.94 per share. Some valuation checks are being made after Eylea HD approval and ongoing Dupixent momentum. A $2 billion factory plan seems to be in the pipeline, following a slip in Eylea sales amid fierce competition. The company continues to remain attractive despite recent share price fluctuations.
Regeneron Pharmaceuticals REGN News Analytics from Thu, 04 Sep 2025 07:00:00 GMT to Sat, 31 Jan 2026 21:37:13 GMT - Rating 6 - Innovation 7 - Information 8 - Rumor 3
